A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

NCT02019277 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Docetaxel
DRUG: Nab-paclitaxel
DRUG: Paclitaxel
DRUG: Pertuzumab
DRUG: Trastuzumab

Sponsor

Hoffmann-La Roche